

LARS KLARESKOG PUBLICATIONS 2016**Peer-reviewed articles**

1. Altawil R, Saevarsdottir S, Wedren S, Alfredsson L, Klareskog L, Lampa J. Remaining Pain in Early Rheumatoid Arthritis Patients Treated With Methotrexate. *Arthritis Care & Research* 2016; 68: 1061-1068.
2. Aulin C, Erlandsson-Harris H, Palmblad K, Klareskog L. INTRAARTICULAR DRUG DELIVERY OF ANTI-HMGB1 IN HYALURONAN GELS FOR CARTILAGE REPAIR. *Osteoarthritis and Cartilage* 2016; 24: S161-S161.
3. Brink M, Hansson M, Mathsson-Alm L, Wijayatunga P, Verheul MK, Trouw LA, Holmdahl R, Ronnelid J, Klareskog L, Rantapaa-Dahlqvist S. Rheumatoid factor isotypes in relation to antibodies against citrullinated peptides and carbamylated proteins before the onset of rheumatoid arthritis. *Arthritis Research & Therapy* 2016; 18.
4. Catrina AI, Joshua V, Klareskog L, Malmstrom V. Mechanisms involved in triggering rheumatoid arthritis. *Immunological Reviews* 2016; 269: 162-174.
5. Chemin K, Klareskog L, Malmstrom V. Is rheumatoid arthritis an autoimmune disease? *Current Opinion in Rheumatology* 2016; 28: 181-188.
6. Chemin K, Pollastro S, James E, Ge CR, Albrecht I, Herrath J, Gerstner C, Tandre K, Rizzi TS, Ronnblom L, Catrina A, Holmdahl R, Klareskog L, de Vries N, Malmstrom V. A Novel HLA-DRB1*10:01-Restricted T Cell Epitope From Citrullinated Type II Collagen Relevant to Rheumatoid Arthritis. *Arthritis & Rheumatology* 2016; 68: 1124-1135.
7. Eriksson K, Nise L, Kats A, Luttrupp E, Catrina AI, Askling J, Jansson L, Alfredsson L, Klareskog L, Lundberg K, Yucel-Lindberg T. Prevalence of Periodontitis in Patients with Established Rheumatoid Arthritis: A Swedish Population Based Case-Control Study. *Plos One* 2016; 11.
8. Folkersen L, Brynedal B, Diaz-Gallo LM, Ramskold D, Shchetynsky K, Westerlind H, Sundstrom Y, Schepis D, Hensvold A, Vivar N, Eloranta ML, Ronnblom L, Brunak S, Malmstrom V, Catrina A, Moerch UGW, Klareskog L, Padyukov L, Berg L. Integration of Known DNA, RNA and Protein Biomarkers Provides Prediction of Anti-TNF Response in Rheumatoid Arthritis: Results from the COMBINE Study. *Molecular Medicine* 2016; 22: 322-328.
9. Frisell T, Hellgren K, Alfredsson L, Raychaudhuri S, Klareskog L, Askling J. Familial aggregation of arthritis-related diseases in seropositive and seronegative rheumatoid arthritis: a register-based case-control study in Sweden. *Annals of the Rheumatic Diseases* 2016; 75: 183-189.

10. Gomez-Cabrero D, Almgren M, Sjöholm LK, Hensvold AH, Ringh MV, Tryggvadóttir R, Kere J, Scheynius A, Acevedo N, Reinius L, Taub MA, Montano C, Aryee MJ, Feinberg JI, Feinberg AP, Tegner J, Klareskog L, Catrina AI, Ekstrom TJ. High-specificity bioinformatics framework for epigenomic profiling of discordant twins reveals specific and shared markers for ACPA and ACPA-positive rheumatoid arthritis. *Genome Medicine* 2016; 8.
11. Han B, Pouget JG, Slowikowski K, Stahl E, Lee CH, Diogo D, Hu XL, Park YR, Kim E, Gregersen PK, Dahlqvist SR, Worthington J, Martin J, Eyre S, Klareskog L, Huizinga T, Chen WM, Onengut-Gumuscu S, Rich SS, Wray NR, Raychaudhuri S, Psychiat Genom C. A method to decipher pleiotropy by detecting underlying heterogeneity driven by hidden subgroups applied to autoimmune and neuropsychiatric diseases. *Nature Genetics* 2016; 48: 803-+.
12. Jiang X, Kallberg H, Chen ZM, Arlestig L, Rantapaa-Dahlqvist S, Davila S, Klareskog L, Padyukov L, Alfredsson L. An Immunochip-based interaction study of contrasting interaction effects with smoking in ACPA-positive versus ACPA-negative rheumatoid arthritis. *Rheumatology* 2016; 55: 149-155.
13. Jiang X, Sundstrom B, Alfredsson L, Klareskog L, Rantapaa-Dahlqvist S, Bengtsson C. High sodium chloride consumption enhances the effects of smoking but does not interact with SGK1 polymorphisms in the development of ACPA-positive status in patients with RA. *Annals of the Rheumatic Diseases* 2016; 75: 943-945.
14. Kastbom A, Forslind K, Ernestam S, Geborek P, Karlsson JA, Petersson IF, Saevarsdóttir S, Klareskog L, van Vollenhoven RF, Lundberg K. Changes in the anticitrullinated peptide antibody response in relation to therapeutic outcome in early rheumatoid arthritis: results from the SWEFOT trial. *Annals of the Rheumatic Diseases* 2016; 75: 356-361.
15. Krishnamurthy A, Joshua V, Hensvold AH, Jin T, Sun M, Vivar N, Ytterberg AJ, Engstrom M, Fernandes-Cerqueira C, Amara K, Magnusson M, Wigerblad G, Kato J, Jimenez-Andrade JM, Tyson K, Rapecki S, Lundberg K, Catrina SB, Jakobsson PJ, Svensson C, Malmstrom V, Klareskog L, Wahamaa H, Catrina AI. Identification of a novel chemokine-dependent molecular mechanism underlying rheumatoid arthritis-associated autoantibody-mediated bone loss. *Annals of the Rheumatic Diseases* 2016; 75: 721-729.
16. Raza K, Klareskog L, Holers VM. Predicting and preventing the development of rheumatoid arthritis. *Rheumatology* 2016; 55: 1-3.
17. Saevarsdóttir S, Klareskog L, Hansson M, Eriksson J, Johannesson M, Holmdahl R, Skriner K, Serre G, Mathsson-Alm L, van Vollenhoven RF, van der Woude D, Allaart R, Alfredsson L, McInnes I, Ronnelid J, Askling J. Do specific ACPAs or other autoantibodies in a novel assay predict response to methotrexate monotherapy in patients with early and DMARD-naïve RA? *Scandinavian Journal of Rheumatology* 2016; 45: 19-19.

18. Sieberts SK, Zhu F, Garcia-Garcia J, Stahl E, Pratap A, Pandey G, Pappas D, Aguilar D, Anton B, Bonet J, Eksi R, Fornes O, Guney E, Li HD, Marin MA, Panwar B, Planas-Iglesias J, Poglayen D, Cui J, Falcao AO, Suver C, Hoff B, Balagurusamy VSK, Dillenberger D, Neto EC, Norman T, Aittokallio T, Ammad-ud-din M, Azencott CA, Bellon V, Boeva V, Bunte K, Chheda H, Cheng L, Corander J, Dumontier M, Goldenberg A, Gopalacharyulu P, Hajiloo M, Hidru D, Jaiswal A, Kaski S, Khalfaoui B, Khan SA, Kramer ER, Marttinen P, Mezlini AM, Molparia B, Pirinen M, Saarela J, Samwald M, Stoven V, Tang H, Tang J, Torkamani A, Vert JP, Wang B, Wang T, Wennerberg K, Wineinger NE, Xiao GH, Xie Y, Yeung R, Zhan XW, Zhao C, Greenberg J, Kremer J, Michaud K, Barton A, Coenen M, Mariette X, Miceli C, Shadick N, Weinblatt M, de Vries N, Tak PP, Gerlag D, Huizinga TWJ, Kurreeman F, Allaart CF, Bridges SL, Criswell L, Moreland L, Klareskog L, Saevarsdottir S, Padyukov L, Gregersen PK, Friend S, Plenge R, Stolovitzky G, Oliva B, Guan YF, Mangravite LM, Rheumatoid Arth C. Crowdsourced assessment of common genetic contribution to predicting anti-TNF treatment response in rheumatoid arthritis. *Nature Communications* 2016; 7.
19. Too CL, Muhamad NA, Ilar A, Padyukov L, Alfredsson L, Klareskog L, Murad S, Bengtsson C, My ESG. Occupational exposure to textile dust increases the risk of rheumatoid arthritis: results from a Malaysian population-based case-control study. *Annals of the Rheumatic Diseases* 2016; 75: 997-1002.
20. van Heemst J, Hensvold AH, Jiang X, van Steenbergen H, Klareskog L, Huizinga TWJ, van der Helm-van Mil A, Catrina AI, Toes REM, Lundberg K, van der Woude D. Protective effect of HLA-DRB1*13 alleles during specific phases in the development of ACPA-positive RA. *Annals of the Rheumatic Diseases* 2016; 75: 1891-1898.
21. Wigerblad G, Bas DB, Fernades-Cerqueira C, Krishnamurthy A, Nandakumar KS, Rogoz K, Kato J, Sandor K, Su J, Jimenez-Andrade JM, Finn A, Farinotti AB, Amara K, Lundberg K, Holmdahl R, Jakobsson PJ, Malmstrom V, Catrina AI, Klareskog L, Svensson CI. Autoantibodies to citrullinated proteins induce joint pain independent of inflammation via a chemokine-dependent mechanism. *Annals of the Rheumatic Diseases* 2016; 75: 730-738.
22. Yarwood A, Viatte S, Okada Y, Plenge R, Yamamoto K, Barton A, Symmons D, Raychaudhuri S, Klareskog L, Gregersen P, Worthington J, Eyre S, Braggss, Raci. Loci associated with N-glycosylation of human IgG are not associated with rheumatoid arthritis: a Mendelian randomisation study. *Annals of the Rheumatic Diseases* 2016; 75: 317-320.